

DAFTAR PUSTAKA

1. Arnaud L, Chasset F, Martin T. Immunopathogenesis of systemic lupus erythematosus: An update. *Autoimmun Rev.* 2024;23:103648.
2. Fatoye F, Gebrye T, Mbada C. Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. *Rheumatol Int.* 2022;42:2097.
3. Hamijoyo L, Sapartini G, Rahmadi AR, Wachjudi RG, Dewi S, Ghrahani R, et al. Comparison of clinical presentation and outcome of childhood-onset and adulthood-onset of systemic lupus erythematosus among Indonesian patients. *Lupus.* 2022;31(6):759-764.
4. Setiabudiawan B, Ghrahani R. 423 Indonesian epidemiologic data of paediatric systemic lupus erythematosus. *Lupus Sci Med.* 2017;4:A201.1-A201.
5. Amezcua-Guerra LM, Higuera-Ortiz V, Arteaga-García U, Gallegos-Nava S, Hübbe-Tena C. Performance of the 2012 Systemic Lupus International Collaborating Clinics and the 1997 American College of Rheumatology classification criteria for systemic lupus erythematosus in a real-life scenario. *Arthritis Care Res (Hoboken).* 2015;67:437–41.
6. Crawford LR, Neparidze N. Refractory autoimmune hemolytic anemia in a systemic lupus erythematosus patient: A clinical case report. *Clin Case Rep.* 2022;10:1-4.
7. Hassan MR, Hossain A, Mahata J, Srivastava V, Sarkar S. Hematological manifestation of Pediatric Systemic Lupus Erythematosus (SLE) – A single centered cross-sectional study. *Journal of Family Medicine and Primary Care* 2024;13(5):1787-1792.
8. Samanta M, Nandi M, Mondal R, Hazra A, Sarkar S, Sabui T, Kundu CK, Biswas A. Childhood lupus nephritis: 12 years of experience from a developing country's perspective. *Eur J Rheumatol.* 2017;4(3):178-183.
9. Chang JC, Xiao R, Mercer-Rosa L, Knight AM, Weiss PF. Child-onset systemic lupus erythematosus is associated with a higher incidence of myopericardial manifestations compared to adult-onset disease. *Lupus.* 2018;27(13):2146-2154.
10. Blachut D, Mazurkiewicz M, Schulz M, Cieśla J, Przywara-Chowaniec B, Tomasiak A. Update: Heart Failure in Systemic Lupus Erythematosus. *Applied Sciences.* 2025; 15(3):1-17.
11. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Ann Rheum Dis* 2024;83:15–29.
12. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus, *QJM* 1993; 86(7): 447–458.
13. Lupu VV, Lupu A, Jechel E, Starcea IM, Stoleriu G, Ioniuc I, et al. The role of vitamin D in pediatric systemic lupus erythematosus - a double pawn in the immune and microbial balance. *Front Immunol.* 2024; 15: 1-13.
14. Mahfudz MZ, Tjahjono HA, Salim IA, Mutaqin F. Correlation of Vitamin D and nutritional status in pediatric systemic lupus erythematosus. *Pediatrics Sciences Journal.* 2023. 4(1): 16-19.
15. Jiang L, Zhi S, Wei C, Rong Z, Zhang H. Serum 25(OH)D levels are associated with disease activity and renal involvement in initial-onset childhood systemic lupus erythematosus. *Front Pediatr.* 2023; 11: 1-9.

16. Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus. *Paediatr Drugs*. 2021 Jul;23(4):331-347.
17. Yusof MYM, Smith EMD, Ainsworth S, Armon K, Beresford MW, Brown M, *et al*. Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope. *Rheumatology Advances in Practice*. 2023; 7(3): 1-7.
18. Thakral A, Klein-Gitelman MS. An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus. *Rheumatol Ther*. 2016;3(2):209-219.
19. Eknayan G, Lameire N, Jadoul M, Grams ME, Ashuntantang GE, Bavanandan S, *et al*. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. *Kidney International* (2024) 105 (Suppl 1S), S1–S69.
20. Castro M, Ugolini-Lopes M, Borba EF, Bonfá E, Seguro LPC. Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression. *Lupus*. 2018;27:2215–9.
21. Palazzuoli A, Mazzeo P, Fortunato M, Cadeddu DC, Mariano E, Salzano A, *et al*. The Changing Role of Loop Diuretics in Heart Failure Management across the Last Century. *Journal of Clinical Medicine*. 2024; 13(6): 1-20.
22. Suszek D, Dubaj M, Bigosiński K, Dembowska A, Kaniewski M, Sielwanowska W, *et al*. Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus. *Reumatologia*. 2024;62(3):187-195.
23. Chong KM, Jiang H, Lo EAG, Hong WZ, Wong ETY, Chan GC, *et al*. Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps. *J. Clin. Med*. 2024; 13(2):1-15.
24. Sobhy N, Niazy MH, Siam I. Secondary amenorrhea in a cohort of Egyptian systemic lupus erythematosus patients. *The Egyptian Rheumatologist*. 2020; 42: 27–30.
25. Quan XY, Chen HT, Liang SQ, Yang C, Yao CW, Xu YZ, *et al*. Revisited Cyclophosphamide in the Treatment of Lupus Nephritis. *BioMed Research International*. 2022: 1-7.
26. Xu M, Tian LL, Li XL, Bao C, Zhang HW, Chen HW. Ovarian function in patients with systemic lupus erythematosus: Pathogenesis, drug application and prospective therapies. *World J Exp Med* 2024; 14(2): 1-7.
27. Krag S, Larsen D, Albertsen BK, Glerup M. Risk of ocular hypertension in children treated with systemic glucocorticoid. *Acta Ophthalmol*. 2021: 99: e1430–e1434.
28. Mendes N, Alves PJ, Barros M, Rodrigues JM, Machado J. A Narrative Review of Current Striae Treatments. *Healthcare (Basel)*. 2022;10(12): 1-7.
29. Gacem O, Abba K, Mansouri N, Ayad N, Zeroual Z, Arrada Z, *et al*. Use of corticosteroids in childhood systemic lupus erythematosus: experience from a pediatric rheumatology center. *Rheumatology* 2022;61(Suppl 2):ii20.
30. Lokhande AJ, Venkataram M. Striae Distensae Treatment Review and Update. *Indian Dermatology Online Journal* 2019; 10(4):380-395.
31. Fabri F. Severe Striae and Steroid Acne as Side Effects Caused by Long-Term Systemic Corticosteroid Treatment: A Case Report and Review of The Literature. *IJMRCR*. 2018; 1: 1-8.

32. Ardhayani IAA, Sutomo R, Sumadiono. Prediktor Kualitas Hidup Anak Dengan Lupus Eritematosus Sistemik (LES) (Tesis). Yogyakarta: Universitas Gadjah Mada. 2019. p.
33. Amiruddin MM, Othman A, Rahman AA, Ilias MI. Childhood Systemic Lupus Erythematosus (cSLE) and Its Psychological Impact: Dual Tertiary Centre Experience. *Malaysian Journal of Medicine and Health Sciences*. 2024; 20(Supp3): 98-103.
34. Eid R, Hammad A, Korkor MS, Fathy AA, Abd El-Ghafaar DM. Health Related Quality of Life in Juvenile-Onset Systemic Lupus Erythematosus: A Questionnaire-Based Study. *Matern Child Health J*. 2023;27(9):1578-88.
35. Jannah M, Nasution TH, Hidayah R, Rizqinda LL, Ulfi NW, Dewi ES. The Relationship Between Family Support and Stress Levels of People with Lupus at the Kupu Parahita Indonesia Foundation. *International Journal of Care Scholars*. 2022; 5(3): 52–9.
36. Mizukami A, Trinh MT, Hoang TP, Shibanuma A, Ong KIC, Jimba M. Determinants of health-related quality of life among patients with systemic lupus erythematosus in Hanoi, Vietnam. *BMC Rheumatol* 2023. 22;7(1): 1-8.
37. Kamath N, Rawat A, Singh A. Childhood Systemic Lupus Erythematosus. Standard Treatment Guidelines 2022. New Delhi: Indian Academy of Pediatrics. 2022. p. 1-12.
38. Listiyono F, Sumadiono, Satria CD, Murni IK. Predictors of mortality in children with systemic lupus erythematosus. *Paediatr Indones*. 2019;59:1-6.
39. Rahmatika, Handoyo R, Kesoema TA. Therapeutic Exercise in Systemic Lupus Erythematosus: Review Article. *Indonesian Journal of Physical Medicine and Rehabilitation*. 2019: 7(1): 44 -54.
40. Blaess J, Geneton S, Goepfert T, Appenzeller S, Bordier G, et al. Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force. *RMD Open* 2024;10:1-9.
41. Wu JY, Yeh, KW, Huang JL. Early predictors of outcomes in pediatric lupus nephritis: Focus on proliferative lesions. *Seminars in Arthritis and Rheumatism*. 2014; 43(4):513-520.
42. Rodríguez-Lozano AL, Rivas-Larrauri FE, García-de la Puente S, Alcivar-Arteaga DA, González-Garay AG. Prognostic Factors at Diagnosis Associated With Damage Accrual in Childhood-Onset Systemic Lupus Erythematosus Patients. *Front Pediatr*. 2022;22(10):1-9.
43. Lu Y, Huang XM. Autoimmune hemolytic anemia as an initial presentation in children with systemic lupus erythematosus: two case reports. *J Int Med Res*. 2022;50(8):1-8.
44. Tiaaza F, Amine MB, Asmaa S, et al. Dilated cardiomyopathy in systemic lupus erythematosus: A pediatric case report. Available from: <https://www.researchsquare.com/article/rs-339594/v1>. Accessed: 26 April 2025.
45. Li Z, Zhu S, Tang W, Zhang H, Le W, Luo S, Zhou C, Wang Y, Xu S, Hu W, Li S. Clinical features and two-year outcomes in systemic lupus erythematosus patients with heart failure and reduced, mid-range and preserved ejection fractions. *Lupus*. 2025;34(1):88-101.

46. Valenzuela-Almada MO, Hocaoglu M, Dabit JY, Osei-Onomah SA, Basiaga ML, Orandi AB, *et al.* 2022. Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study. *Arthritis Care Res.* 2022;74(5):728-732.
47. Gamal SM, Fouad N, Yosry N, Badr W, Sobhy N. Disease characteristics in patients with juvenile- and adult-onset systemic lupus erythematosus: A multi-center comparative study. *Arch Rheumatol* 2022;37(2):280-287



Luaran Modifikasi Protokol Akibat Efek Samping Obat Berat pada Pasien Lupus Eritematosus Sistemik Berat dengan Manifestasi Anemia Hemolitik Autoimun Berat, Nefritis Lupus Kelas II, Kardiomiopati Dilatasi dan Gagal Jantung dengan Preserved Ejection Fraction
Surya Wijaya, dr. Cahya Dewi Satria, M.Kes, Sp.A (K)
Universitas Gadjah Mada, 2025 | Diunduh dari <http://etd.repository.ugm.ac.id/>